Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. (DRUG) Revenue
Annual & quarterly revenue history · segment & region breakdown
DRUG · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBright Minds Biosciences Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-09-30 | $0.00B | +$0.00B | — |
| 2024-09-30 | $0.00B | +$0.00B | — |
| 2023-09-30 | $0.00B | +$0.00B | — |
| 2022-09-30 | $0.00B | +$0.00B | — |
| 2021-09-30 | $0.00B | +$0.00B | — |
| 2020-09-30 | $0.00B | +$0.00B | — |
| 2019-09-30 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Bright Minds Biosciences Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Bright Minds Biosciences Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Bright Minds Biosciences Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DRUG revenue · 4 questionsDRUG's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Bright Minds Biosciences Inc. SEC filings · GAAP · Bright Minds Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026